Elevated Natural Killer Cell-Mediated Cytotoxicity Is Associated with Cavity Formation in Pulmonary Tuberculosis Patients.

Publisher: Hindawi Publishing Corporation Country of Publication: Egypt NLM ID: 101627166 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-7156 (Electronic) Linking ISSN: 23147156 NLM ISO Abbreviation: J Immunol Res Subsets: MEDLINE

Original Publication: Cairo, Egypt : Hindawi Publishing Corporation, [2014]-

Cytotoxicity, Immunologic*; Killer Cells, Natural/*immunology ; Lung/*pathology ; Mycobacterium tuberculosis/*immunology ; Tuberculosis, Pulmonary/*immunology; Adult ; Cells, Cultured ; Female ; Granzymes/analysis ; Granzymes/metabolism ; Humans ; Killer Cells, Natural/metabolism ; Lung/immunology ; Lung/microbiology ; Male ; Middle Aged ; Primary Cell Culture ; Tuberculosis, Pulmonary/blood ; Tuberculosis, Pulmonary/microbiology ; Tuberculosis, Pulmonary/pathology ; Young Adult

Cavitation is a major pathological feature of pulmonary tuberculosis (TB). The study is aimed at investigating the mechanism of natural killer (NK) cells participating the cavity formation during Mycobacterium tuberculosis (MTB) infection. Human peripheral blood samples were donated by pulmonary TB patients with cavity or not. Real-time quantitative PCR and enzyme-linked immunosorbent assay were performed to analyze the expression of cytokines secreted by NK cells. And the cytotoxicity of NK cells was compared between two groups. Our data showed that NK cells were more abundant in cohorts of cavity. Increased abundance of granzyme A and granzyme B was observed in culture supernatants of NK cells isolated from cavitary TB patients, which also resulted in a higher level of nonviable MTB-infected monocytes. Our data firstly demonstrates that NK cells participate in cavity formation in pulmonary TB patients. The elevated level and increased cytotoxicity of NK cells accelerate the cavitary formulation.
Competing Interests: The authors declare that they have no competing interests.
(Copyright © 2021 Shanshan Li et al.)

Front Immunol. 2019 May 17;10:1116. (PMID: 31156653)
J Immunol. 2009 Mar 15;182(6):3638-49. (PMID: 19265142)
Semin Roentgenol. 1993 Apr;28(2):109-18. (PMID: 8516687)
Am J Pathol. 2018 Jul;188(7):1666-1675. (PMID: 29753789)
Nat Immunol. 2015 Sep;16(9):927-32. (PMID: 26193080)
Lancet Infect Dis. 2020 Jun;20(6):e117-e128. (PMID: 32482293)
Curr Opin Immunol. 2016 Feb;38:67-74. (PMID: 26706497)
J Infect Dis. 2000 Mar;181(3):1194-7. (PMID: 10720554)
Chest. 2000 Jan;117(1):103-9. (PMID: 10631206)
Curr Opin Immunol. 2014 Aug;29:56-61. (PMID: 24792889)
Am J Respir Crit Care Med. 1999 Jan;159(1):143-8. (PMID: 9872832)
Clin Infect Dis. 2012 Mar;54(6):e51-4. (PMID: 22198790)
Eur Respir Rev. 2018 Feb 28;27(147):. (PMID: 29491034)
Respir Med. 1998 Mar;92(3):493-7. (PMID: 9692111)
Front Pediatr. 2019 Aug 27;7:350. (PMID: 31508399)
Nat Protoc. 2008;3(6):1101-8. (PMID: 18546601)
Annu Rev Immunol. 2005;23:225-74. (PMID: 15771571)
Tuberculosis (Edinb). 2006 Sep;86(5):337-48. (PMID: 16359922)
J Clin Microbiol. 2007 Dec;45(12):4064-6. (PMID: 17928422)
Eur J Radiol. 2004 Aug;51(2):139-49. (PMID: 15246519)
Clin Exp Immunol. 2003 May;132(2):283-8. (PMID: 12699418)
Am J Respir Crit Care Med. 2014 Jul 1;190(1):9-18. (PMID: 24713029)
J Clin Microbiol. 2010 Oct;48(10):3593-9. (PMID: 20720028)
Am Rev Respir Dis. 1993 Apr;147(4):958-61. (PMID: 8466133)

EC 3.4.21.- (GZMB protein, human)
EC 3.4.21.- (Granzymes)
EC 3.4.21.78 (GZMA protein, human)

Date Created: 20211014 Date Completed: 20220207 Latest Revision: 20220207

20231215

PMC8505075

10.1155/2021/7925903

34646890